Moderna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Moderna yıllık ortalama 76.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler growing yılda ortalama 78.4% oranında artmaktadır. Moderna'in özkaynak karlılığı 43.7% ve net marjı 43.4%'dir.

Anahtar bilgiler

76.3%

Kazanç büyüme oranı

76.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	18.9%
Gelir büyüme oranı	78.4%
Özkaynak getirisi	43.7%
Net Marj	43.4%
Son Kazanç Güncellemesi	31 Dec 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Moderna nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BRSE:0QF Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Dec 22	19,263	8,362	1,132
30 Sep 22	21,390	11,765	958
30 Jun 22	22,995	14,055	848
31 Mar 22	22,600	14,638	758
31 Dec 21	18,471	12,202	567
30 Sep 21	11,831	7,061	445
30 Jun 21	7,019	3,495	325
31 Mar 21	2,732	598	241
31 Dec 20	803	-747	188
30 Sep 20	246	-597	135
30 Jun 20	106	-488	115
31 Mar 20	52	-505	106
31 Dec 19	60	-514	110
30 Sep 19	82	-535	122
30 Jun 19	106	-499	112
31 Mar 19	122	-459	105
31 Dec 18	135	-402	94
30 Sep 18	192	-299	72
30 Jun 18	192	-280	70
31 Mar 18	199	-266	65
31 Dec 17	206	-270	65
31 Dec 16	108	-230	57

Kaliteli Kazançlar: 0QF yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: 0QF 'nin mevcut net kar marjları (43.4%) geçen yılın (66.1%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0QF son 5 yılda karlı hale geldi ve kazançlarını yıllık 76.3% oranında artırdı.

Büyüme Hızlandırma: 0QF 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 0QF geçtiğimiz yıl negatif kazanç büyümesine ( -31.5% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( -18.2% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 0QF 'nin Özsermaye Getirisi ( 43.7% ) ödenmemiş olarak değerlendirilmektedir.

Moderna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin